Full Press Release Details
Pharmaceuticals, Inc.
Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
NEW YORK, NY, February 6, 2015
- Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE MKT: ATNM), a biopharmaceutical
company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the pricing
of an underwritten public offering of an aggregate 4,444,444 shares of its common stock and warrants to purchase an aggregate of
3,333,333 shares of the Company's common stock at a combined price to the public of $4.50. The shares of common stock and warrants
will be issued separately. The warrants will be exercisable for a period of 4 years following the issuance thereof at an exercise
price of $6.50 per share. The warrants will be certificated, and will be delivered to the investors by physical delivery at the
closing. There is no established public trading market for the warrants and Actinium does not expect a market to develop in the
future. In addition, Actinium has granted the underwriters a 30-day option to purchase up to an additional 666,666 shares
of common stock and warrants to purchase 499,999 shares of common stock solely to cover over-allotments, if any. The offering is
expected to close on or about February 11, 2015, subject to customary closing conditions.
to Actinium from this offering is expected to be $20,000,000, before deducting underwriting discounts and commissions and other
estimated offering expenses payable by Actinium. If the warrants are exercised in full, Actinium will receive additional proceeds
of approximately $21,666,665. Actinium currently intends to use the net proceeds from the sale of securities for general corporate
purposes, including capital expenditures, the advancement of its product candidates in clinical trials, such as Iomab -B
Phase 3 clinical trial and Actimab - A Phase 2 clinical trial, preclinical trials, to support licensing activities, and to
meet working capital needs.
(UK) Ltd. acted as sole book-running manager for the offering. MLV& Co. acted as co-manager for the offering.
The offering is being conducted pursuant to
a shelf registration statement that was previously filed with, and declared effective by, the U.S. Securities and Exchange Commission
("SEC"). Before investing, you should carefully read the prospectus supplement, the accompanying prospectus and the information
incorporated by reference therein for information about Actinium and the offering. A preliminary prospectus supplement and the
accompanying prospectus relating to the offering have been filed with the SEC and are available at the SEC's website at www.sec.gov.
A final prospectus supplement related to the offering will be filed with the SEC. Copies of the preliminary prospectus supplement,
the final prospectus supplement (when available) and accompanying prospectus relating to these securities may also be obtained
from the offices of Laidlaw & Company (UK) Ltd., 546 Fifth Avenue, 5th Floor,
New York, NY, 10036, telephone: 212-953-4900.
press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these
securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of such jurisdiction.
Actinium Pharmaceuticals
Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted
payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary
delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals
in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical Iomab-B will be used, upon approval, in preparing
patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single,
pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary
endpoint of durable complete remission. The Company's second program, Actimab-A, is continuing its clinical development in a Phase
1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
Statement for Actinium Pharmaceuticals, Inc.
news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.
These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results
to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product
development, product potential or financial performance. No forward-looking statement can be guaranteed and actual results may
differ materially from those projected. Actinium undertakes no obligation to publicly update any forward-looking statement, whether
as a result of new information, future events or otherwise.
Actinium Pharmaceuticals, Inc.
VP Investor Relations and Finance